Carl Zeiss Meditec AG: Postponement of the Annual General Meeting 2020 in the course of tightening up the regulations for public events

Jena, Germany | 17 March 2020 | Medical Technology

On the basis of the decree of the President of the State Administration Office of Thuringia (Landesverwaltungsamt Thüringen) of 14 March 2020, according to which "events and meetings of people with 50 or more persons must be prohibited from now until further notice", the Management Board of Carl Zeiss Meditec AG has decided to postpone the Annual General Meeting, which was scheduled for Tuesday, 24 March 2020 (published in the Federal Gazette (Bundesanzeiger) of 11 February 2020); it will therefore not take place. A new date will be announced in time.

Press Contact

Sebastian Frericks
Director Investor Relations
Carl Zeiss Meditec AG
Phone: +49 3641 220-116
investors .meditec @zeiss .com

Brief Profile

Carl Zeiss Meditec AG (ISIN: DE 0005313704), which is listed on the MDAX and TecDAX of the German stock exchange, is one of the world’s leading medical technology companies. The Company supplies innovative technologies and application-oriented solutions designed to help doctors improve the quality of life of their patients. The Company offers complete solutions, including implants and consumables, to diagnose and treat eye diseases. The Company creates innovative visualization solutions in the field of microsurgery. With 3,232 employees (as of 30 September 2019) worldwide, the Group generated revenue of €1,459.3m in fiscal year 2018/19 (as of 30 September).

The Group’s head office is located in Jena, Germany, and it has subsidiaries in Germany and abroad; more than 50 percent of its employees are based in the USA, Japan, Spain and France. The Center for Application and Research (CARIn) in Bangalore, India and the Carl Zeiss Innovations Center for Research and Development in Shanghai, China, strengthen the Company's presence in these rapidly developing economies. Around 41 percent of Carl Zeiss Meditec AG’s shares are in free float. The remaining approx. 59 percent are held by Carl Zeiss AG, one of the world’s leading groups in the optical and optoelectronic industries.

For further information visit: www.zeiss.com/med
 

Press Contact

Sebastian Frericks
Director Investor Relations
Carl Zeiss Meditec AG
Phone: +49 3641 220-116
investors .meditec @zeiss .com

Share
Further Articles

Carl Zeiss Meditec increases revenue in first six months of 2019/20

COVID-19 pandemic leads to significant slowdown in second quarter

Carl Zeiss Meditec generated revenue of €714.9m in the first six months of 2019/20 (prior year: €667.2m), achieving g...

May 11, 2020

Changes in Executive Leadership

Jim Mazzo, current President of Ophthalmic Devices and Head of Ophthalmic Devices Strategic Business Unit for ZEISS w...

Mar 9, 2020

Successful start to fiscal year 2019/20 for Carl Zeiss Meditec with profitable growth

Growth in all strategic business units and regions

Carl Zeiss Meditec generated revenue of €369.7m in the first three months of fiscal year 2019/20, which corresponds t...

Feb 10, 2020